miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma

Table 3

Univariate and multivariate Cox regression analysis of OS and clinical features in UCEC patients.

Characteristics	Total (N)	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Clinical stage (stage I and stage II versus stage III and stage IV)	545	3.774 (2.484–5.732)	<0.001	3.912 (1.711–8.946)	0.001
Primary therapy outcome (PD, SD, and PR versus CR)	475	0.125 (0.075–0.208)	<0.001	0.299 (0.130–0.689)	0.005
Age (≤60 versus >60)	543	2.002 (1.236–3.242)	0.005	1.944 (0.868–4.355)	0.106
Weight (≤80 versus >80)	522	1.032 (0.676–1.576)	0.885
Height (≤160 versus >160)	518	1.115 (0.728–1.708)	0.616
BMI (≤30 versus >30)	514	0.942 (0.616–1.442)	0.784
Histological type (mixed and serous versus endometrioid)	545	0.366 (0.241–0.557)	<0.001	1.285 (0.615–2.685)	0.505
Residual tumor (R0 versus R1 and R2)	407	3.081 (1.725–5.503)	<0.001	1.951 (0.811–4.694)	0.136
Histologic grade ( versus and )	534	22.795 (3.172–163.794)	0.002	156521500.831 (0.000-Inf)	0.997
Tumor invasion (%) (<50 versus ≥50)	469	3.124 (1.909–5.112)	<0.001	1.111 (0.532–2.320)	0.779
Menopause status (peri and post versus pre)	499	1.070 (0.466–2.457)	0.874
Hormones therapy (no versus yes)	343	0.872 (0.412–1.845)	0.72
Diabetes (no versus yes)	445	1.188 (0.733–1.925)	0.485
Radiation therapy (no versus yes)	521	0.586 (0.375–0.914)	0.018	0.320 (0.165–0.622)	<0.001
Surgical approach (minimally invasive versus open)	522	0.731 (0.474–1.127)	0.156
hsa-miR-149-3p (low versus high)	545	2.559 (1.637–4.002)	<0.001	2.393 (1.161–4.935)	0.018